Rosetta Genomics Ltd, a developer and provider of microRNA-based molecular diagnostics, announces the commercial availability of miRview® mets² ("miRview mets two"), a microRNA-based test that identifies the primary origin of tumors of uncertain or unknown origin. The new test, which builds on the technology and know-how of miRview mets, offers physicians and patients a larger panel of 42 tumors that can be identified, an increase from the 25 tumors that can be identified in the previous version of the test. In addition, the new assay offers identification of sarcomas, lymphomas, and other non-epithelial malignancies, as well as more histologic subtypes. Furthermore, the test features improved classifiers, which incorporate clinical, biological, and molecular knowledge.
miRview mets² leverages the proprietary technologies used in miRview mets, described in the development and validation study published in the June 2010 issue of Modern Pathology, and in the March 2008 issue of Nature Biotechnology. Preliminary data on miRview mets² were presented at the Fourth Annual AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development in September 2010. Rosetta Genomics anticipates the final data from the validation study will be presented during the first half of 2011.
In order to effectively direct the physicians in the diagnostic process, miRview mets² offers physicians and patients a wide panel of 42 identifiable tumor origins, high accuracy, and biologically motivated and easy-to-understand proprietary classifiers. Furthermore, to truly assist physicians in deciding which origin to further explore from their list of suspected origins, miRview mets² was designed to provide only one or two most likely suspected origins, with the vast majority of cases providing just a single origin or answer.
The test’s overall performance is very high, with a sensitivity for a single answer prediction of 90%, and an overall sensitivity of 85%. Overall specificity was 97% to 99%.
Currently, miRview mets² is not available for patients and physicians residing in the State of New York.
Source: Rosetta Genomics Ltd